This website is intended for US healthcare professionals only.
VYEPTI permanent J-code (J3032) is now available. Learn more
FIND A VYEPTI-READY INFUSION CENTER IN YOUR AREA
You are about to leave the VYEPTI website for healthcare professionals
VYEPTI Dosing and Administration Video Coming Soon
Request a representative
Interested in discussing VYEPTI with a sales representative in your area? Request a meeting now.
Contact VYEPTI CONNECT
VYEPTI CONNECT Liaisons are available to help you with access and reimbursement support and more, by phone.
Phone number: 833-4-VYEPTI (833-489-3784)
Available Monday through Friday, 8 am-8 pm (ET)
Fax number: 866-868-7071
VYEPTI product support
For general VYEPTI product support, please call
833-4-VYEPTI (833-489-3784).
Stay connected
Want to keep up with the latest news and updates about migraine prevention with VYEPTI?
VYEPTI GO
Discover the patient resources we have to support your patients along their VYEPTI treatment journey.
Adverse reactions
To report suspected adverse reactions, contact Lundbeck at 1-800-455-1141 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
If you have patients who are willing to share their VYEPTI stories, they may share their experiences here.
You may also be interested in:
IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications
VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.
INDICATION
VYEPTI is indicated for the preventive treatment of migraine in adults.
Warnings and Precautions
Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.
Adverse Reactions
The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.
For more information, please see the Prescribing Information and Patient Information.
IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications
VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.
INDICATION
VYEPTI is indicated for the preventive treatment of migraine in adults.
Warnings and Precautions
Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.
Adverse Reactions
The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.
For more information, please see the Prescribing Information and Patient Information.
© 2021 Lundbeck. All rights reserved. VYEPTI, VYEPTI CONNECT, and VYEPTI GO are trademarks of Lundbeck Seattle BioPharmaceuticals, Inc. EPT-B-100032v4
This website is intended for US healthcare professionals only.
